Portal de Periódicos da CAPES

Novel Inflammatory Marker in Dialysis Patients: YKL‐40

2012; Wiley; Volume: 17; Issue: 2 Linguagem: Inglês

10.1111/j.1744-9987.2012.01141.x

1744-9987

Gülay Ulusal Okyay, Ramazan Erdem Er, Merve Yasemin Tekbudak, Özge Tuğçe Paşaoğlu, Salih İnal, Kürşad Öneç, Hatîce Paşaoğlu, Kadriye Altok, Ülver Derici, Yasemin Erten,

Studies on Chitinases and Chitosanases

Abstract YKL‐40 has been introduced as a marker of inflammation in different clinical situations. The association between YKL‐40 and inflammation in chronic renal failure patients has not been researched currently. The objectives of this study were to establish serum YKL‐40 concentrations in dialysis patients with chronic renal failure compared to healthy subjects and to explore its relationships with a proinflammatory cytokine, interleukine‐6 (IL‐6) and an acute phase mediator, high sensitivity C‐reactive protein (hs‐CRP). The study population included hemodialysis patients ( N = 43; mean age of 40.9 ± 14.5), peritoneal dialysis patients ( N = 38; mean age of 45.8 ± 13.7) and healthy subjects ( N = 37; mean age of 45.5 ± 10.6). Serum concentrations of YKL‐40, IL‐6, hs‐CRP and routine laboratory measures were evaluated. Compared to the healthy subjects, hemodialysis and peritoneal dialysis patients had higher concentrations of YKL‐40, IL‐6, hs‐CRP, as well as lower concentrations of hemoglobin, serum albumin and high density lipoprotein‐cholesterol ( P < 0.001). YKL‐40 concentrations were positively correlated with serum creatinine ( P < 0.001, r = 0.495), IL‐6 ( P < 0.001, r = 0.306), hs‐CRP ( P = 0.001, r = 0.306) levels and inversely correlated with hemoglobin ( P = 0.002, r = −0.285), serum albumin ( P < 0.001, r = −0.355) and high density lipoprotein‐cholesterol ( P = 0.001, r = −0.306). In multivariate regression analysis YKL‐40 was associated with creatinine, serum albumin and hs‐CRP concentrations after adjustments with covariates. Dialysis patients with chronic renal failure have elevated serum YKL‐40 concentrations. Associations with standard inflammatory parameters suggest that YKL‐40 might be a novel inflammatory marker in this population.